TWO SIGMA INVESTMENTS, LP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 95 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2020. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.

Quarter-by-quarter ownership
TWO SIGMA INVESTMENTS, LP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q2 2023$625,092
-30.7%
18,423
-26.6%
0.00%
-33.3%
Q1 2023$902,522
+7.8%
25,084
-15.8%
0.00%0.0%
Q3 2022$837,000
-88.7%
29,780
-89.1%
0.00%
-87.5%
Q2 2022$7,377,000
-5.4%
273,620
+19.5%
0.02%
+4.3%
Q1 2022$7,798,000
+4.2%
228,948
+18.2%
0.02%
+43.8%
Q4 2021$7,482,000
+117.0%
193,641
-1.6%
0.02%
+60.0%
Q4 2020$3,448,000
-40.4%
196,792
-49.5%
0.01%
-52.4%
Q3 2020$5,783,000
+239.4%
389,942
+197.5%
0.02%
+162.5%
Q2 2020$1,704,000
+1752.2%
131,094
+282.1%
0.01%
Q2 2019$92,00034,3080.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2020
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 1,017,524$20,961,0007.56%
Octagon Capital Advisors LP 561,398$11,565,0004.36%
COMMODORE CAPITAL LP 369,951$7,621,0003.04%
Opaleye Management Inc. 985,000$20,291,0002.98%
VR Adviser, LLC 1,240,610$25,557,0002.77%
TSP Capital Management Group, LLC 359,229$7,400,0002.61%
RTW INVESTMENTS, LP 3,908,947$80,524,0001.26%
Ghost Tree Capital, LLC 250,000$5,150,0001.21%
Tri Locum Partners LP 196,672$4,051,0001.00%
Redmile Group, LLC 3,387,788$69,788,0000.98%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders